Ellenbarrie Industrial Gases IPO GMP rises to 6%; issue subscribed 9% on Day 2
The initial public offering (IPO) of Ellenbarrie Industrial Gases was subscribed 9% so far on the second day of bidding on Wednesday, up from 8% on Day 1.
ADVERTISEMENT As of 10:03 am, the IPO had received bids for 12,95,222 shares, or 9% of the total issue size of 1,51,08,983 shares. The retail investor portion was subscribed 15%, while the non-institutional investor (NII) category saw a 9% subscription. The qualified institutional buyer (QIB) segment was yet to be subscribed.
In the grey market, Ellenbarrie Industrial Gases shares were trading at a premium of Rs 25–26, up from Rs 7–9 on Day 1. This means the GMP has risen to around 6% from 1.75%.
Also Read:These 10 penny stocks under Rs 10 surged 200-570% in last 1 year. Do you own any?The public issue includes a fresh equity issuance worth Rs 400 crore along with an offer for sale (OFS) of 1.13 crore shares. Ahead of the launch, the company successfully secured Rs 256 crore from anchor investors.
ADVERTISEMENT The price band has been set at Rs 380 to Rs 400 per share, with a minimum application size of 37 shares. The shares are proposed to be listed on both the NSE and BSE.The IPO proceeds will be utilised to repay debt amounting to Rs 210 crore, establish a 220 TPD air separation unit at the company's Uluberia-II plant at a cost of Rs 104.5 crore, and meet general corporate requirements. Eastern India Gases Ltd (EIGL) also plans to commission three new plants by FY26, aiming to increase its total installed capacity from 3,861 TPD to 4,551 TPD.
ADVERTISEMENT Also Read:Jio Financial surges over 50% from March lows: Will the momentum sustain?Founded over five decades ago, EIGL manufactures and supplies a wide range of industrial gases such as oxygen, nitrogen, argon, and acetylene, along with speciality gases, medical gases, and cryogenic storage systems. It operates nine facilities across East, South, and Central India, servicing industries like steel, pharmaceuticals, defence, healthcare, and railways.
ADVERTISEMENT The company reported a 26.7% PAT margin in FY25 with net profit of Rs 83.3 crore, EBITDA margin of 35.8%, and return on equity of 16.9%. At the upper end of the price band, the stock is valued at 62.9x FY25 earnings.
Also Read: Coforge among 10 high-conviction stock ideas that can rally up to 52%
ADVERTISEMENT
SBI Securities has rated the IPO as Subscribe, citing EIGL's improving margin profile, strong client base, strategic capacity expansion, and attractive valuation compared to listed peers like Linde India.
(Disclaimer: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Economic Times)
(You can now subscribe to our ETMarkets WhatsApp channel)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30 minutes ago
- Time of India
Haffkine to quiz 2 pharmaceutical firms for selling it ‘blacklisted' medicines for government hospitals in Maharashtra
Mumbai: Haffkine Bio-Pharmaceuticals procurement cell will be seeking explanations from two pharmaceutical firms after it came to light that medicines ordered for govt hospitals across the state in Feb had been declared "not of standard quality" and blacklisted by Employees' State Insurance Corporation (ESIC) just two months earlier. In Dec, ESIC issued a circular blacklisting specific drugs from seven pharmaceutical companies, citing test results that found these medicines to be of substandard quality and directing that no further orders be placed with them. However, Haffkine Bio-Pharmaceuticals placed large supply orders with two of the listed firms. This resulted in the procurement of nearly 21.9 lakh vials of Pantoprazole 40mg/10ml injection worth Rs 2.5 crore from Galpha Laboratories Ltd, and 88,650 tablets of Vildagliptin 50mg, along with Metformin Hydrochloride 1000mg worth nearly Rs 12.6 lakh, from Bajaj Healthcare Ltd. Pantoprazole is used to treat acid-related stomach issues such as ulcers and acid reflux, while Vildagliptin with Metformin is prescribed to manage type 2 diabetes by controlling blood sugar levels. Although Haffkine is no longer the primary authority for medicine procurement, it was granted permission to utilise the remaining Rs 131.6 crore to restock medicines at state-run hospitals through a Govt Resolution (GR). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Memperdagangkan CFD Emas dengan salah satu spread terendah? IC Markets Mendaftar "The procurement process must be based on ESIC rate contracts as received on the e-Aushadhi platform," the GR stated. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai A senior official at the procurement cell confirmed that they are looking into the matter. "We have been orally informed by ESIC that the issue pertained to specific batches. Nevertheless, we have sought written responses from the companies as well as from ESIC. These will be submitted to higher authorities, and payments to the companies will be withheld until a reasonable explanation is provided," the official said, but did not provide the amount of payments to be withheld. Abhay Pandey, of the All Food and Drug Licence Holders Foundation, who flagged the issue with medical education department officials, alleged that the existing rate contract was arbitrarily selected by Haffkine without verifying the blacklisting status of the companies or conducting additional tests on the medicines. Haffkine officials did not respond when asked whether random sampling of the procured products was conducted in accordance with the GR. Dr Shashi Kolnoorkar, state ESIC director (Medical), said the blacklisting order came from the Delhi headquarters and that appropriate action had been taken at the time. When asked whether the blacklisting applied to specific batches or constituted a complete ban on the medicines in question, he referred the query to the ESIC head office. Attempts were made to reach Dr Neeta Garbiyal, deputy medical commissioner at the ESIC head office, who had signed the blacklist circular, but she was unavailable for comment. File pic
Time of India
34 minutes ago
- Time of India
Gujarat emerges as second highest CSR spender in country
1 2 Ahmedabad/Vadodara: Gujarat recorded a sharp rise in corporate social responsibility (CSR) spending in FY 2024, emerging as the second highest contributor in the country after Maharashtra. According to data by the Union ministry of corporate affairs, companies operating in the state spent Rs 2,707.54 crore on CSR activities during the fiscal, registering a robust 31.4% growth over the previous year's Rs 2,060.02 crore. The number of contributing companies also rose to 3,789, indicating growing corporate participation in social development. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad The rise in CSR places Gujarat ahead of traditionally strong industrial hubs like Karnataka, Tamil Nadu, and Delhi, all of which saw more modest increases. While Maharashtra retained its lead with Rs 6,065.95 crore in CSR spend, Gujarat not only narrowed the gap but also posted the highest year-on-year percentage growth among the top five states. Pankaj Kamliya, chief operations officer, Gujarat CSR Authority (GCSRA), said, "The spending by ArcelorMittal Nippon Steel India Limited has substantially grown in the past year, which is reflected in the overall spending. Moreover, the spending in Vadodara district has dramatically improved. Overall, Gujarat-based companies made good profits, which directly led to an increase in CSR spending. The state govt's proactive approach is also helping materialise CSR projects widely, with better local support, a conducive environment to execute projects, and thorough analysis of the requirement of each district and plans of action developed by the govt. " According to experts, Gujarat has seen a substantial number of large industries setting and expanding their footprint in the last decade. Many of them were profitable in recent years, with increasing volumes year after year. The strong presence of large companies in the manufacturing sector has driven the trend of increased spending. "While Karnataka has long been India's IT powerhouse, Gujarat has led in manufacturing. Today, the China Plus One strategy has positioned Gujarat as a key global supplier, driving strong corporate profits. At the same time, a slowdown in the IT sector has squeezed margins for tech firms, impacting Karnataka's economic edge," said Parthesh Vyas, co-CEO of Vadodara-based Fulcrum, a leading consulting, advising, and research firm in the social and CSR sector, which released the 'Bharat CSR Performance Report FY 2023-24' on Monday. "Moreover, while investments in IT may be tapering, Gujarat continues to attract some of the highest foreign investments—thanks to its world-class infrastructure, including excellent roads, ports, and connectivity. This combination has propelled Gujarat to the number two position in corporate profitability, ahead of Karnataka," said Vyas. Notably, CSR spending in Gujarat nearly tripled from Rs 984.37 crore in FY 2020 to Rs 2,707.54 crore in FY 2024. Companies with registered offices or significant operations in Gujarat have increasingly aligned their CSR goals with local developmental priorities, particularly in education, environment, and gender equity. Education emerged as the largest sectoral beneficiary in FY 2024, drawing Rs 1,424.47 crore in funding, up 39.3% from the previous year. Healthcare, even though drawing the second highest CSR spending, witnessed a marginal decline of 5.2% in FY 2024. "One reason could be the govt's increased focus on public health post-Covid. Flagship schemes like Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) have enabled millions to access top-tier treatment across the country, possibly reducing the immediate need for corporate intervention in the healthcare sector through CSR," said Arun Mathai Marette, co-CEO of Fulcrum. In terms of districts, Ahmedabad stood out with the highest CSR inflow at Rs 760.99 crore, accounting for over a quarter of the state's total. Vadodara, Gandhinagar, Jamnagar, and Surat also figured prominently, reflecting the concentration of corporate hubs and industrial zones in these regions.
Time of India
37 minutes ago
- Time of India
Namma Yatri turns city-level Ebdita positive in core markets; launches welfare fund for drivers
Academy Empower your mind, elevate your skills Bengaluru-based ride-hailing platform Namma Yatri is now city-level Ebdita positive in its core markets, including the Karnataka capital, and plans to scale services further, cofounder and COO Shan M S told ET on Wednesday.' The idea is to have sustainable growth. In the core markets where we are operating, like Bengaluru, we are already city-level Ebdita positive,' Shan M S, cofounder and COO of Namma Yatri, told ET at the second edition of Namma Sarathi Sangama on added that the platform has seen consistent month-on-month growth across cities, including Bengaluru and parts of to the platform's dashboard, Namma Yatri has completed over 10.38 crore rides, generating more than Rs 1,700 crore in earnings for its 6.13 lakh registered drivers. In Bengaluru alone, the app has facilitated 8.7 crore the event, Namma Yatri also announced a new initiative, the Namma Driver Welfare Trust , for its driver partners across Karnataka. The fund will be independently governed, with 2% of the platform's revenue set aside to provide financial support to eligible drivers. To qualify, drivers must complete 50–60 rides per company is now looking to expand its services and invest in digitising public transport systems in cities like Bengaluru, Chennai, and Kolkata.
